Actively Recruiting
Evaluating Individualized Photothermal Therapy Using Navilas Laser System in Intermediate Age-related Macular Degeneration A Randomized, Double-Blind, Controlled Trial
Led by OD-OS MacuTherm GmbH · Updated on 2026-10-21
240
Participants Needed
10
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating photothermal therapy using an individually tailored treatment plan proposed by Macula Explorer, delivered by the NavilasAE Laser System, to treat individuals aged 60 to 90 with intermediate Age-related Macular Degeneration iAMD. The study aims to see if this approach can safely improve photoreceptor health and slow disease progression by preserving the Ellipsoid Zone Integrity EZI. Participants will be randomly assigned to receive either the photothermal therapy or a sham treatment in the study eye. The study involves 12 visits monthly for the first three months, then quarterly visits continue for up to two years. The therapy is delivered via a specialized laser system with personalized dosing. During the study, participants will undergo eye exams and assessments to monitor photoreceptor health and disease progression, including evaluating the Ellipsoid Zone Integrity at 12 months as the primary outcome. Secondary outcomes include changes in drusen progression, rates of progression to advanced forms of AMD, and visual acuity loss over 24 months. Participants will be closely monitored throughout the study to assess safety and effectiveness over this period.
CONDITIONS
Brief Title
MacuTherm Performance Study in Patients With iAMD
Research Team
J
Jan Tode, Prof. Dr. med.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here